← Back to headlines
MoonLake Receives Upgrade from Rothschild & Co Redburn on Potential FDA Approval
MoonLake Immunotherapeutics has been upgraded by Rothschild & Co Redburn, with analysts citing the potential for FDA approval of the company's lead drug. This upgrade reflects increased confidence in the drug's market prospects.
19 Mar, 15:40 — 19 Mar, 15:40
Sources
Showing 1 of 1 sources
